163 related articles for article (PubMed ID: 36688961)
1. Antiangiogenic activity of the penicillin derivative TAP7f in melanoma.
Barrionuevo E; Cornier PG; Delpiccolo CML; Mata EG; Roguin LP; Blank VC
J Mol Med (Berl); 2023 Mar; 101(3):249-263. PubMed ID: 36688961
[TBL] [Abstract][Full Text] [Related]
2. A Penicillin Derivative Exerts an Anti-Metastatic Activity in Melanoma Cells Through the Downregulation of Integrin αvβ3 and Wnt/β-Catenin Pathway.
Barrionuevo E; Cayrol F; Cremaschi GA; Cornier PG; Boggián DB; Delpiccolo CML; Mata EG; Roguin LP; Blank VC
Front Pharmacol; 2020; 11():127. PubMed ID: 32158394
[TBL] [Abstract][Full Text] [Related]
3. A novel penicillin derivative induces antitumor effect in melanoma cells.
Blank V; Bellizzi Y; Zotta E; Cornier PG; Delpiccolo CML; Boggián DB; Mata EG; Roguin LP
Anticancer Drugs; 2018 Jun; 29(5):416-428. PubMed ID: 29494356
[TBL] [Abstract][Full Text] [Related]
4. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
Langenkamp E; Zwiers PJ; Moorlag HE; Leenders WP; St Croix B; Molema G
Anticancer Drugs; 2012 Feb; 23(2):161-72. PubMed ID: 22075979
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic effect of Biophytum sensitivum is exerted through its cytokine modulation activity and inhibitory activity against VEGF mRNA expression, endothelial cell migration and capillary tube formation.
Guruvayoorappan C; Kuttan G
J Exp Ther Oncol; 2007; 6(3):241-50. PubMed ID: 17552364
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effect of a penicillin derivative combined with thapsigargin in melanoma cells.
Bellizzi Y; Cornier PG; Delpiccolo CML; Mata EG; Blank V; Roguin LP
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3361-3373. PubMed ID: 35751681
[TBL] [Abstract][Full Text] [Related]
8. Contribution of endoplasmic reticulum stress, MAPK and PI3K/Akt pathways to the apoptotic death induced by a penicillin derivative in melanoma cells.
Bellizzi Y; Anselmi Relats JM; Cornier PG; Delpiccolo CML; Mata EG; Cayrol F; Cremaschi GA; Blank VC; Roguin LP
Apoptosis; 2022 Feb; 27(1-2):34-48. PubMed ID: 34773171
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion.
Kaliski A; Maggiorella L; Cengel KA; Mathe D; Rouffiac V; Opolon P; Lassau N; Bourhis J; Deutsch E
Mol Cancer Ther; 2005 Nov; 4(11):1717-28. PubMed ID: 16275993
[TBL] [Abstract][Full Text] [Related]
11. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
[TBL] [Abstract][Full Text] [Related]
12. Antitumoral and antimetastatic effect of antiangiogenic plasmids in B16 melanoma: Higher efficiency of the recombinant disintegrin domain of ADAM 15.
Daugimont L; Vandermeulen G; Defresne F; Bouzin C; Mir LM; Bouquet C; Feron O; Préat V
Eur J Pharm Biopharm; 2011 Aug; 78(3):314-9. PubMed ID: 21316447
[TBL] [Abstract][Full Text] [Related]
13. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
Gao J; Hu H; Wang X
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators.
Hamsa TP; Kuttan G
Drug Chem Toxicol; 2012 Jan; 35(1):57-70. PubMed ID: 22145808
[TBL] [Abstract][Full Text] [Related]
15. CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth.
Chung TW; Kim SJ; Choi HJ; Kwak CH; Song KH; Suh SJ; Kim KJ; Ha KT; Park YG; Chang YC; Chang HW; Lee YC; Kim CH
J Mol Med (Berl); 2013 Feb; 91(2):271-82. PubMed ID: 22935775
[TBL] [Abstract][Full Text] [Related]
16. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
[TBL] [Abstract][Full Text] [Related]
17. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
18. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
[TBL] [Abstract][Full Text] [Related]
19. Total saponins from Albizia julibrissin inhibit vascular endothelial growth factor-mediated angiogenesis in vitro and in vivo.
Cai W; Li Y; Yi Q; Xie F; Du B; Feng L; Qiu L
Mol Med Rep; 2015 May; 11(5):3405-13. PubMed ID: 25607254
[TBL] [Abstract][Full Text] [Related]
20. Piper longum inhibits VEGF and proinflammatory cytokines and tumor-induced angiogenesis in C57BL/6 mice.
Sunila ES; Kuttan G
Int Immunopharmacol; 2006 May; 6(5):733-41. PubMed ID: 16546703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
